Drug Type Small molecule drug |
Synonyms EMB 001C, EMB-001, EMB-001C + [1] |
Target |
Action inhibitors, positive allosteric modulator |
Mechanism CYP11B1 inhibitors(Steroid 11-beta-hydroxylase inhibitors), GABAA receptor positive allosteric modulator(Gamma-aminobutyric acid A receptor positive allosteric modulator) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H11ClN2O2 |
InChIKeyADIMAYPTOBDMTL-UHFFFAOYSA-N |
CAS Registry604-75-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Smoking Cessation | Phase 3 | United States | 19 May 2021 | |
| Smoking Cessation | Phase 3 | United States | 19 May 2021 | |
| Tobacco Use Disorder | Phase 3 | United States | 19 May 2021 | |
| Tobacco Use Disorder | Phase 3 | United States | 19 May 2021 | |
| Metastatic Colorectal Carcinoma | Phase 2 | China | 18 Dec 2025 | |
| Cocaine-Related Disorders | Phase 2 | United States | 29 Jul 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 13 Dec 2018 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 13 Dec 2018 | |
| Bone metastases | Phase 2 | United States | 13 Dec 2018 | |
| Bone metastases | Phase 2 | China | 13 Dec 2018 |





